#Japan #Novo Nordisk #Obesity Treatment #Hinode #Hinode Town

Novo Nordisk Pharma and Hinode Town Unite for Obesity Solutions

On June 2, 2023, Novo Nordisk Pharma Co., Ltd., represented by CEO Akihiro Kotani, signed a partnership agreement with Hinode Town, located in Tokyo's Nishitama District, led by Mayor Hiroshi Azuma. This collaboration focuses on developing effective strategies to combat obesity, aiming to extend the health span of local residents while optimizing healthcare costs and addressing health inequality.

Currently, about 60% of municipalities across Japan lack specialized medical institutions for obesity treatment within their administrative boundaries. This absence can lead to significant disparities in diagnosis and treatment for those requiring care. In response, this initiative represents a pioneering effort in Japan to establish a model for improving access to proper obesity treatment through strengthened collaboration within healthcare networks.

Hinode Town's national health insurance data reveals alarming statistics, with one in six insurance beneficiaries evaluated in specific health examinations identified as having metabolic syndrome. Furthermore, two-thirds experience lifestyle-related diseases. These findings underscore the urgency of addressing obesity—a significant health risk factor within the community.

Under this joint agreement, Hinode Town will provide healthcare guidance to residents with a Body Mass Index (BMI) of 25 or higher who wish to receive support. This will involve personalized consultations led by nurses or public health experts, along with dietitians. Moreover, individuals meeting specific criteria will be referred to local clinics or specialized medical facilities for further evaluation and treatment, ensuring that residents have access to necessary healthcare services.

Obesity often suffers from stigma and misconceptions surrounding self-responsibility, making it difficult for individuals to seek proper medical attention. However, under medical supervision, effective treatment not only helps in weight management but also contributes to the improvement of associated health conditions such as diabetes and cardiovascular diseases.

Novo Nordisk Pharma has previously established similar agreements aimed at addressing obesity in various municipalities, including Chiba City, Kasugai City, Asahikawa City, Hirosaki City, and Hiroshima Prefecture, solidifying its commitment to collaborative public health initiatives. The aim is to use the insights gained from this partnership to model accessible healthcare solutions that minimize regional disparities.

Overview of the Collaboration Agreement

Purpose

The primary objective of the partnership between Hinode Town and Novo Nordisk Pharma is to enhance the health and well-being of local residents through collaborative initiatives targeting obesity treatment and prevention.

Areas of Collaboration

1. Development of obesity treatment strategies.
2. Utilization of health and medical data.
3. Sharing information on healthcare policy trends and national best practices.
4. Implementation of necessary activities to achieve the goals of the partnership.

Roles of Each Party

• - Novo Nordisk Pharma:

- Raise awareness about obesity and promote the appropriate use of treatment medications.
- Provide insights into healthcare policy trends and successful national case studies.
- Highlight successful examples within Hinode Town for dissemination across Japan.

• - Hinode Town:

- Conduct health consultations and encourage eligible residents to seek treatment.
- Coordinate with the local medical community and healthcare providers.
- Leverage health and medical data for effective program implementation.

Expected Outcomes

• - Enhanced knowledge among residents regarding obesity and its consequences.
• - Increased opportunities for residents to access appropriate obesity treatment.
• - Future reduction in healthcare costs due to prevention of conditions leading to complications such as dialysis.
• - Advancement in treatment options for obesity.

Timeline

• - June 2, 2026: Signing of the collaboration agreement.
• - June 5, 2026: Expected implementation of the initiative.

Conclusion

The partnership between Novo Nordisk Pharma and Hinode Town symbolizes a transformative approach toward addressing obesity within communities by fostering collaboration between public and private sectors. With a shared goal of improving health outcomes, this innovative effort holds promise for creating sustainable healthcare accessibility for all residents.

More About Novo Nordisk and Hinode Town

Novo Nordisk is a leading healthcare company founded in 1923 and headquartered in Denmark. Its mission focuses on addressing serious chronic diseases, drawing on extensive experience in diabetes management. The company aims to promote scientific innovation and expand access to treatment options across the globe.

Hinode Town is situated in western Tokyo’s Tama region, known for its beautiful natural surroundings, including Mount Hinode. The town strives to blend modernization with nature, aiming for a community where residents can thrive in a harmonious environment. The town's long-term plan aims to foster a sustainable and pleasant living area for all its inhabitants, promoting wellness and togetherness.